Medical Sedation News
-
Belgian scale-up Oncomfort raises €10 million in Series A funding co-led by Debiopharm and Crédit Mutuel Innovation
Oncomfort, the Belgian inventor of and leader in Digital Sedation - a new method for relieving patients’ pain and anxiety without medication - today announces the completion of a €10 million Series A funding round co-led by two prominent institutional investors: Debiopharm and Crédit Mutuel Innovation. Oncomfort plans to use this investment to further develop its innovative ...
By Oncomfort
-
Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant
ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity Approval for post-operative respiratory depression expected in 2026 and community drug overdose thereafter ENA-001 works peripherally by inhibiting Big Potassium (BK) ion channels in the carotid bodies, which are located in the neck. By inhibiting these channels, ...
-
EvoEndo Poised to Transform Clinical Endoscopy Practice with the EvoEndo Single-Use Unsedated Transnasal Endoscopy (TNE) System
EvoEndo, Inc. (“EvoEndo”), a medical device company which developed a single use system that allows for unsedated Transnasal Endoscopy (TNE), has announced the completion of an $8.4 million Series A financing round led by founding investor TLP Investment Partners LLC (TLP) and including the Sunshine Charitable Foundation and the Jill and Paul Meister family. Proceeds from the ...
By EvoEndo
-
EvoEndo Announces US FDA 510(k) Clearance for Single-Use Unsedated Transnasal Endoscopy (TNE) System
EvoEndo’s Single-Use Endoscopy System or the “EvoEndo System” eliminates the need for general anesthesia or conscious sedation during routine upper endoscopic procedures The EvoEndo System is being distributed by Micro-Tech Endoscopy USA with commercial sales slated to begin following completion of first clinical cases at several pediatric facilities EvoEndo, Inc. ...
By EvoEndo
-
Gene therapy for butterfly children: 5-year follow-up published in the New England Journal of Medicine
Epidermolysis bullosa (EB), better known as butterfly baby disease, is a genetic disorder that involves the continuous formation of bullous lesions on the skin, due to very small mechanical trauma and minimal rubbing, which strongly impact the quality of life of these patients. Depending on the type of mutated gene, it is distinguished in different forms, of which the most severe are Junctional ...
-
Co-creative Innovation with BioWin
ONCOMFORT, GIGA CONSCIOUSNESS, ISIA LAB AND PILIPILI LAUNCH A CO-CREATION PROJECT WITH SUPPORT OF THE BIOWIN HEALTH CLUSTER FRAMEWORK The project aims at objectivizing Digital Sedation™, paving the way for the first management system for non-pharmacological sedation for use in daily clinical practice. In 2017, Oncomfort created a medical device for Digital Sedation™, a digital ...
By Oncomfort
-
EvoEndo and Micro-Tech Endoscopy Announce Partnership for Single-Use Unsedated Endoscopy System
EvoEndo®, Inc. (“EvoEndo”), a medical device company developing systems for unsedated endoscopy, today announced the signing of a distribution agreement with Micro-Tech Endoscopy USA, Inc. (“Micro-Tech”). The agreement, whereby Micro-Tech will distribute the EvoEndo® Single-Use Endoscopy System in the US, is expected to begin pending US FDA 510(k) clearance. ...
By EvoEndo
-
EvoEndo Raises $10.1 Million to Make Unsedated Transnasal Endoscopy a Reality for Patients and Physicians
EvoEndo Inc., (“EvoEndo” or “the Company”) a preclinical medical device company developing systems for unsedated Transnasal Endoscopy (TNE), announced it has secured $10.1M in equity financing. The funding round, which included a variety of family offices and early-stage life science investors, will be used to further EvoEndo’s innovative technology designed to help ...
By EvoEndo
-
Oncomfort receives ISO 13485:2016 certification
ncomfort, the leader in Digital Sedation™, a digital therapy to relieve patient anxiety and pain, today announces that it has obtained the ISO 13485:2016 certification by certification company DARE!! Services. This certification confirms that Oncomfort manages the design, manufacturing and distribution of its Digital Sedation™ medical device and its Sedakit™, in its quality ...
By Oncomfort
-
Liberate Medical Reports Positive Pilot Trial Results of VentFree Respiratory Muscle Stimulator
Applying non-invasive electrical stimulation to the expiratory abdominal muscles may reduce abdominal muscle atrophy and markedly reduce the number of days adult patients require mechanical ventilation – a potentially important finding for weaning ventilated patients, including seriously ill COVID-19 patients, and improving patient outcomes. Liberate Medical today announced the results of ...
-
VentFree Respiratory Muscle Stimulator receives FDA Emergency Use Authorization for Use During COVID-19 Pandemic
Liberate Medical today announced that it has received Federal Drug Administration (FDA) Emergency Use Authorization for its VentFree™ Respiratory Muscle Stimulator, intended to be used to reduce disuse atrophy of the abdominal wall muscles, which may reduce the number of days adult patients require mechanical ventilation, including those patients with COVID-19. Reducing the time patients ...
-
Check-Cap Announces Positive Results from U.S. Pilot Study of C-Scan System
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first and only preparation-free ingestible scanning capsule based system for the prevention of colorectal cancer through the detection of precancerous polyps, today announced positive results from the ...
-
Liberate Medical Announces CE Marking for its VentFree Respiratory Muscle Stimulator
Liberate Medical, a medical device company developing novel non-invasive electrical muscle stimulation devices to help patients with pulmonary conditions, today announced that it has received CE marking for its VentFree™ Respiratory Muscle Stimulator and ISO 13485 certification for its quality management system. The VentFree stimulator applies proprietary non-invasive electrical ...
-
BioQ Pharma Receives Australian Regulatory Approval for Propofol Product - Propofusor 1%
BioQ Pharma Incorporated (“the Company”), a specialty pharmaceutical company, today announced that the Australian Therapeutic Goods Administration (TGA) has approved the Company’s Propofusor product containing 1% propofol in a single-use dispensing system. Uses of the Propofusor include the induction and maintenance of general anesthesia, sedation of mechanically ventilated ...
By BioQ Pharma
-
Liberate Medical’s VentFree Muscle Stimulator Receives Breakthrough Device Designation from the FDA to Reduce Mechanical Ventilation Duration
Liberate Medical, a clinical stage medical device company, focused on the development of novel non-invasive neuromuscular electrical stimulation devices to address pulmonary conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company’s VentFree muscle stimulator. The proposed indication for the device is preventing ...
-
AventaMed partner with PROSA 2018
AventaMed are delighted to partner with PROSA for the 1st European Conference on Pediatric Procedural Sedation and Analgesia in Maastricht, The Netherlands, November 29th & 30th 2018. Come say hello to us at booth 7 and learn more about the Solo TTD. For more information or to schedule a meeting, contact ciara.omahony@aventamed.com PSA represents a relatively new field in modern medicine, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you